Opioid Pharmacotherapy for Young People
If you work in the youth services sector, you may come across young people (aged 12-25) who use opioids and may be dependent – and you might be wondering what treatment looks like for them.
Treatment can include pharmacotherapy.
As opioid dependency and treatment is more common in older age groups1, those working in the youth services space may be less familiar with pharmacotherapy as a treatment option.
This guide provides an overview of opioid pharmacotherapy, including:
- how it works
- pathways to accessing it
- barriers to treatment.
This guide is designed to inform anyone working in the youth sector, and it will also be useful to community members interested in understanding opioid pharmacotherapy.
All service types
Pharmacotherapy
Search for pharmacotherapy services in your area
- Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data collection Canberra: AIHW; 2021 [cited 2021 May 31].
- Recovery Research Institute. Pharmacotherapy Medications [cited 2021 May 31].
- Turning Point. Pharmacotherapy 2021 [cited 2021 May 20].
- Whetton S, Tait R, Chrzanowska A, Donnelly N et al. Quantifying the Social Costs of Pharmaceutical Opioid Misuse and Illicit Opioid Use to Australia in 2015/16. Curtin University: National Drug Research Institute; 2020.
- Australian Institute of Health and Welfare. Opioid harm in Australia and comparisons between Australia and Canada. Canberra: AIHW; 2018.
- Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia 2020 [updated April 16 2021; cited 2020 July 1].
- Chrzanowska A, Man N, Sutherland R, Degenhardt L et al. Trends in Drug-Induced Deaths in Australia, 1997-2019. 2021 [updated 15 April 2021; cited 2021 22 June].
- Lintzeris N, Dunlop A, Masters D. Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. Sydney: NSW Ministry of Health; 2019.
- World Health Organization. World Health Organization Model List of Essential Medicines, 21st list. Geneva: WHO; 2019.
- Gowing L, Ali R, Dunlop A, Farrell M et al. National Guidelines for Medication-Assisted Treatment of Opioid Dependence. Australian Government Department of Health; 2014.
- Drug and Alcohol Office. Clinical Policies and Procedures for the Use of Methadone and Buprenorphine in the Treatment of Opioid Dependence. Government of Western Australia; 2014.
- Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience 2007;9(4):455-70.
- NPS MedicineWise. Suboxone Film 2021 [cited 2021 May 25].
- NPS MedicineWise. Subutex 2021 [cited 2021 May 25].
- Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416-26.
- Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2019;393(10173):778-90.
- Wood P, Opie C, Tucci J, Franklin R, Anderson K. “A lot of people call it liquid handcuffs” – barriers and enablers to opioid replacement therapy in a rural area. Journal of Substance Use. 2019;24(2):150-5.
- World Health Organization. Opioid Overdose - Key facts. 2020 [cited 2021 June 22].
- Brands B, Sproule, B & Marshman, J, editor. Drugs & drug abuse. 3rd ed. Ontario: Addiction Research Foundation; 1998.
20. Campbell A. The Australian Illicit Drug Guide: Every Person's Guide to Illicit Drugs--Their Use, Effects and History, Treatment Options and Legal Penalties: Black Inc; 2001.
21. Australian Government Department of Health. About the take home naloxone pilot 2021 [cited 2021 May 26].
22. Petty J, McNally S, Ryan J. Saving lives: Australian naloxone access model. Melbourne: Penington Institute; 2018.
23. Farrugia A, Fraser S, Dwyer R, Fomiatti R et al. Understanding the impediments to uptake and diffusion of take-home naloxone in Australia: Summary report of project publications and recommendations. Bundoora: La Trobe University; 2020.
24. King T, Kirwan A, Lord S. Opioid pharmacotherapy fees: A long-standing barrier to treatment entry and retention: Centre for Research Excellence into Injecting Drug Use; 2014 [updated February 2015; cited 2021 May 26].